MQC | Jotup

Koil Energy Solutions to Provide Critical Subsea Equipment for Shenandoah Development

Retrieved on:

Thursday, January 19, 2023

HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Koil Energy Solutions, Inc. (OTCQB: KLNG), an international specialist in subsea energy equipment and services, today announced the receipt of an order to provide subsea distribution equipment for the Shenandoah project, a 17,500 psi development in the US Gulf of Mexico.

Key Points:

HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Koil Energy Solutions, Inc. (OTCQB: KLNG), an international specialist in subsea energy equipment and services, today announced the receipt of an order to provide subsea distribution equipment for the Shenandoah project, a 17,500 psi development in the US Gulf of Mexico.
“This award is further validation of our strategy to rebrand and reposition the company from a provider of components to a full systems provider,” said Charles Njuguna, President and CEO of Koil Energy Solutions, Inc.
The multi-million-dollar project is for the provision of 70+ Multi Quick Connect (MQC) plates, which are critical pieces of subsea infrastructure used to enable the transfer of different fluids between subsea systems.
The equipment will be qualified for 20,000 psi applications.

Rapid Micro Biosystems® Announces Publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology

Retrieved on:

Wednesday, December 7, 2022

Pharmacy, EMA, MQC, Security (finance), FDA, Marketing, Pharmaceutical microbiology, Environmental monitoring, Vaccine, Drug Quality and Security Act, CGMP, QC, Automation, COVID-19, Medical device, Fine chemical

LOWELL, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company, providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced the publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology.

Key Points:

LOWELL, Mass., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company, providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, announced the publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology.
This study, published online by the PDA Journal of Pharmaceutical Science and Technology, sought to evaluate colony counters as an automated compendial microbiological test method and references current regulatory guidelines.
In order to simplify validation, all sites followed a modular validation approach that had been developed by the participants.
The modular validation facilitates the efficient implementation of the technology to routine use while complying with regulatory requirements.

Rapid Micro Biosystems Concludes Review of Strategic Alternatives

Retrieved on:

Thursday, December 1, 2022

Marketing, COVID-19, Growth, MQC, Workforce, Security (finance), Sale, Automation, Investment, Vaccine, Management, Risk management

LOWELL, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the Company), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its Board of Directors has concluded its previously announced review of strategic alternatives.

Key Points:

LOWELL, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the Company), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its Board of Directors has concluded its previously announced review of strategic alternatives.
Since August 2022, the Board, in consultation with its legal and financial advisors, has conducted a thorough review of strategic alternatives focused on, among other things, a potential sale, merger or other strategic transaction.
"Following a thorough review of strategic alternatives, the Board determined that the continued execution of managements strategy is the best path forward for the Company and its shareholders, said Jeffrey Schwartz, Chairperson of the Board of Directors.
The Board is confident that managements execution on the Companys current strategic initiatives will drive improved performance.

Rapid Micro Biosystems to Announce Third Quarter 2022 Financial Results on November 10, 2022

Retrieved on:

Wednesday, November 2, 2022

Automation, GLOBE, EST, Nasdaq, Vaccine, Compliance, Company, MQC

LOWELL, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the Company), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2022 financial results on Thursday, November 10th, prior to the market open.

Key Points:

LOWELL, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the Company), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release third quarter 2022 financial results on Thursday, November 10th, prior to the market open.
In conjunction with the release, the Companys management team will host a webcast conference call at 8:30 a.m. EST on Thursday, November 10, 2022.
The live and archived webcast is accessible on the Companys website here and will be available for replay for one year.
The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands.

Rapid Micro Biosystems Announces RMBNucleus™ Mold Alarm for the Growth Direct® System

Retrieved on:

Monday, October 10, 2022

RMBNucleus Mold Alarm is expected to be available on the Growth Direct System before the end of 2022.

Key Points:

RMBNucleus Mold Alarm is expected to be available on the Growth Direct System before the end of 2022.
RMBNucleus Mold Alarm, a new software offering for use on the Growth Direct System, adds rapid detection allowing for early intervention.
RMB is committed to supporting life-saving therapies, one patient at a time, said Rob Spignesi, President and CEO of Rapid Micro Biosystems.
We are excited to introduce RMBNucleus Mold Alarm, which will enable our Growth Direct System to rapidly detect environmental molds in the pharmaceutical manufacturing process.

Rapid Micro Biosystems to Exhibit at the 2022 PDA Pharmaceutical Microbiology Conference

Retrieved on:

Tuesday, October 4, 2022

Vaccine, GLOBE, Parenteral Drug Association, LinkedIn, Nasdaq, Industry, Compliance, CEO, Twitter, Automation, Growth, Conference, MQC, Company, MIT Tech Talk, Pharmaceutical industry

This years conference will be attended by global industry professionals, academia and regulatory authorities and will continue the ongoing tradition of addressing the opportunities and challenges that will shape the future of pharmaceutical microbiology.

Key Points:

This years conference will be attended by global industry professionals, academia and regulatory authorities and will continue the ongoing tradition of addressing the opportunities and challenges that will shape the future of pharmaceutical microbiology.
We are excited to participate in the 2022 PDA Pharmaceutical Microbiology Conference and to showcase the capabilities of the Growth Direct System, said Robert Spignesi, President and CEO of Rapid Micro Biosystems.
The global pharmaceutical manufacturing industry must continue to evolve to keep up with the increasing speed and complexity of todays drug manufacturing processes.
The Companys exhibit booth will include an operational Growth Direct System to demonstrate its rapid detection technology and the benefits of automation and digitization in the quality control lab.

Rapid Micro Biosystems CEO Rob Spignesi to Speak at the 2022 PDA/FDA Joint Regulatory Conference

Retrieved on:

Monday, September 12, 2022

Mr. Spignesis session will begin at 7:15 AM ET and run approximately 25 minutes.

Key Points:

Mr. Spignesis session will begin at 7:15 AM ET and run approximately 25 minutes.
Mr. Spignesi will then be joined by Kham Nguyen, Rapid Micro Biosystems Senior Director, Global Field Service and Validation, for a Q&A session.
The Parenteral Drug Association (PDA) and the U.S. Food and Drug Administration (FDA) are co-sponsoring the PDA/FDA Joint Regulatory Conference, now in its 31st year.
For more information, please visit www.rapidmicrobio.com or follow the company on Twitter at @rapidmicrobio or on LinkedIn .

Rapid Micro Biosystems Announces Review of Strategic Alternatives to Maximize Shareholder Value

Retrieved on:

Friday, August 12, 2022

LOWELL, Mass., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that its Board of Directors has initiated a review of strategic alternatives to maximize shareholder value. The Board has retained Morgan Stanley & Co. LLC as its financial advisor and Goodwin Procter LLP as its legal advisor to assist in its review of a wide range of options including, among other things a sale, merger or other strategic transaction.

Key Points:

As we seek to accelerate this work and best position our business for the future, the Board believes now is the right time to explore alternatives to determine the best path to maximize shareholder value.
There can be no assurance that the strategic alternatives process will result in the company pursuing a particular transaction or any other strategic outcome.
In a separate press release, Rapid Micro Biosystems today announced a business update and its financial results for the second quarter ended June 30, 2022.
Morgan Stanley & Co. LLC is acting as Rapid Micro Biosystems financial advisor and Goodwin Procter LLP as its legal counsel.

Rapid Micro Biosystems Provides Business Update and Reports Second Quarter 2022 Financial Results

Retrieved on:

Friday, August 12, 2022

Total (commercial) revenue for the second quarter of 2022 was $3.9 million, compared to commercial revenue of $5.7 million in the second quarter of 2021.

Key Points:

Total (commercial) revenue for the second quarter of 2022 was $3.9 million, compared to commercial revenue of $5.7 million in the second quarter of 2021.
Total operating expenses were $12.9 million in the second quarter of 2022, compared to $9.1 million in the second quarter of 2021.
Net loss for the second quarter of 2022 was ($13.1) million, compared to ($11.8) million in the second quarter of 2021.
The Company will host a conference call before the market opens today, August 12, 2022, at 8:30 a.m. EST to discuss its second quarter 2022 financial results.

Rapid Micro Biosystems to Announce Second Quarter 2022 Financial Results on August 12, 2022

Retrieved on:

Tuesday, August 9, 2022

MQC, GLOBE, Compliance, Company, Twitter, Vaccine, Automation, Nasdaq, LinkedIn, EST

LOWELL, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the Company), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2022 financial results on Friday, August 12, prior to the market open.

Key Points:

LOWELL, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the Company), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, will release second quarter 2022 financial results on Friday, August 12, prior to the market open.
In conjunction with the release, the Companys management team will host a webcast conference call at 8:30 a.m. EST on Friday, August 12, 2022.
The live and archived webcast is accessible on the Companys website here and will be available for replay for one year.
The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands.